Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a drug shrink nasal polyps in rare disease patients?

NCT ID NCT07592104

Completed Symptom relief Sponsor: Fondazione Policlinico Universitario Agostino Gemelli IRCCS Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at 52 adults with EGPA (a rare inflammatory disease) and severe chronic sinusitis with nasal polyps. They received mepolizumab 300 mg every 4 weeks. The goal was to see if the drug reduces polyp size and improves symptoms like nasal congestion and sense of smell over 12 months. The study was observational, meaning researchers watched what happened in real-life medical practice.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
mepolizumab 300 mg
What this could lead to
If successful, this could show that mepolizumab helps shrink nasal polyps and improve breathing and quality of life for people with EGPA and chronic sinusitis.
What could go wrong
This is an observational study, not a controlled trial, so results may be less reliable. It is also small (52 people) and completed, so findings may not apply to everyone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC RHINOSINUSITIS (CRS) WITH AND WITHOUT NASAL POLYPS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic rhinosinusitis eosinophilic granulomatosis with polyangiitis paranasal sinus disorder sinusitis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CHRONIC RHINOSINUSITIS (CRS) WITH AND WITHOUT NASAL POLYPS EGPA - EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS SINUS DISEASE

Contacts and locations

Locations

  • Fondazione Policlinico Universitario A. Gemelli IRCCS

    Roma, Roma, 00168, Italy

More trials for these conditions

Other studies related to the condition(s) this trial covers.